
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx Inc. reported a robust revenue growth of 19% year-over-year in 2024, with expectations for an additional 17% growth in 2025, reflecting the company's strong operational momentum. The testing volume for the company reached 45,500 in 4Q24, marking a 14% increase from the previous quarter, which underlines the successful implementation of its growth strategies aimed at expanding testing services for transplant patients. Furthermore, CareDx's management has outlined strategic initiatives that target long-term revenue of $500 million and a 20% adjusted EBITDA by 2027, positioning the company favorably for sustainable future growth.
Bears say
CareDx Inc faces significant financial challenges that contribute to a negative outlook on its stock. Key risks include potential reimbursement difficulties for its testing services, which could adversely affect revenues, particularly if competitors develop superior testing alternatives. Additionally, the company’s EBITDA guidance of approximately $31 million, which fell short of market expectations, alongside risks related to regulatory changes, integration of acquisitions, and the protection of intellectual property, further heightens concerns regarding its financial stability.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares